NASDAQ:THTX Theratechnologies (THTX) Stock Forecast, Price & News $2.21 +0.07 (+3.27%) (As of 02:11 PM ET) Add Compare Share Share Today's Range$2.12▼$2.2350-Day Range$0.94▼$3.6052-Week Range$0.90▼$11.06Volume23,321 shsAverage Volume86,885 shsMarket Capitalization$53.48 millionP/E RatioN/ADividend YieldN/APrice Target$36.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Theratechnologies MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,551.4% Upside$36.00 Price TargetShort InterestHealthy0.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.97) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector633rd out of 961 stocksPharmaceutical Preparations Industry292nd out of 448 stocks 3.5 Analyst's Opinion Consensus RatingTheratechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.00, Theratechnologies has a forecasted upside of 1,551.4% from its current price of $2.18.Amount of Analyst CoverageTheratechnologies has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.35% of the float of Theratechnologies has been sold short.Short Interest Ratio / Days to CoverTheratechnologies has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Theratechnologies has recently increased by 126.90%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTheratechnologies does not currently pay a dividend.Dividend GrowthTheratechnologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for THTX. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 4 people have searched for THTX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows1 people have added Theratechnologies to their MarketBeat watchlist in the last 30 days. Previous Next N/A Company Ownership Insider Buying vs. Insider SellingIn the past three months, Theratechnologies insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Theratechnologies are expected to grow in the coming year, from ($0.97) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theratechnologies is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theratechnologies is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Theratechnologies (NASDAQ:THTX) StockTheratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Read More THTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart THTX Stock News HeadlinesSeptember 7, 2023 | finance.yahoo.comTheratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceJuly 31, 2023 | theglobeandmail.comBiopharma Firm Completes Reverse Stock SplitSeptember 21, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.July 31, 2023 | finance.yahoo.comTheratechnologies Completes 1-for-4 Reverse Stock SplitJuly 30, 2023 | msn.comTheratechnologies amends credit facility terms to lower minimum liquidityJuly 28, 2023 | finance.yahoo.comTheratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset ManagementJuly 26, 2023 | fool.comTheratechnologies (TSX: TH)July 21, 2023 | finance.yahoo.comTheratechnologies Announces the Resignation of One of Its Directors, Mr. Gary LittlejohnSeptember 21, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.July 12, 2023 | finance.yahoo.comTheratechnologies Reports Second Quarter 2023 Financial Results and Business UpdatesJuly 12, 2023 | washingtonpost.comTheratechnologies: Fiscal Q2 Earnings SnapshotMay 9, 2023 | finance.yahoo.comTheratechnologies Reports on its Annual Meeting of ShareholdersMay 4, 2023 | finance.yahoo.comTheratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment ComparisonApril 13, 2023 | markets.businessinsider.comJonesTrading Sticks to Their Buy Rating for Theratechnologies (THTX)April 12, 2023 | finance.yahoo.comTheratechnologies Reports Financial Results and Business Updates for First Quarter 2023April 12, 2023 | finance.yahoo.comTheratechnologies Reports Financial Results and Business Updates for First Quarter 2023April 3, 2023 | finance.yahoo.comTheratechnologies to Announce First Quarter 2023 Financial Results and Provide Business UpdateMarch 14, 2023 | finance.yahoo.comTheratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor ModelMarch 7, 2023 | financialpost.comTheratechnologies Receives Nasdaq Notification Letter Regarding Share PriceDecember 17, 2022 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Theratechnologies Inc. - THTXNovember 25, 2022 | finance.yahoo.comTheratechnologies Is An Underappreciated HIV-Focused Company, Analyst SaysOctober 18, 2022 | finance.yahoo.com10 Best Low Price Pharma Stocks To Buy Now - Yahoo FinanceOctober 6, 2022 | markets.businessinsider.comTheratechnologies Receives FDA Approval For Intravenous Push Administration Of TrogarzoOctober 3, 2022 | globenewswire.comTheratechnologies' Trogarzo® Approved by FDA for 30-Second - GlobeNewswireOctober 2, 2022 | uk.investing.comAstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know By Benzinga - Investing.com UKSeptember 19, 2022 | globenewswire.comTheratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference - GlobeNewswireSeptember 19, 2022 | finance.yahoo.comTheratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc ConferenceSee More Headlines Receive THTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address THTX Company Calendar Last Earnings7/12/2023Today9/21/2023Next Earnings (Confirmed)9/26/2023Fiscal Year End11/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:THTX CUSIPN/A CIK1512717 Webwww.theratech.com Phone(514) 336-7800Fax514-331-9691Employees144Year Founded1993Price Target and Rating Average Stock Price Forecast$36.00 High Stock Price Forecast$36.00 Low Stock Price Forecast$36.00 Forecasted Upside/Downside+1,543.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,240,000.00 Net Margins-45.09% Pretax Margin-44.44% Return on EquityN/A Return on Assets-42.64% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.59 Sales & Book Value Annual Sales$80.06 million Price / Sales0.66 Cash FlowN/A Price / Cash FlowN/A Book Value($0.93) per share Price / Book-2.35Miscellaneous Outstanding Shares24,200,000Free FloatN/AMarket Cap$53.00 million OptionableNot Optionable Beta1.25 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Paul Lévesque (Age 59)Pres, CEO & Director Comp: $1.31MMr. Philippe Dubuc M.B.A. (Age 56)MBA, Sr. VP & CFO Comp: $449.76kMr. Jocelyn Lafond L.L.M. (Age 55)LL.B., Gen. Counsel & Corp. Sec. Comp: $325.86kDr. Christian Marsolais Ph.D. (Age 60)Sr. VP & Chief Medical Officer Comp: $466.81kMr. John Leasure (Age 58)Global Commercial Officer Comp: $513.95kHon. Andre Dupras M.Sc. (Age 59)VP of HR More ExecutivesKey CompetitorsImmix BiopharmaNASDAQ:IMMXFSD PharmaNASDAQ:HUGEHookipa PharmaNASDAQ:HOOKClearside BiomedicalNASDAQ:CLSDVistagen TherapeuticsNASDAQ:VTGNView All CompetitorsInstitutional OwnershipOsaic Holdings Inc.Bought 10,000 shares on 8/21/2023Ownership: 1.835%Two Sigma Securities LLCSold 27,711 shares on 8/14/2023Ownership: 0.223%Cibc World Market Inc.Sold 11,000 shares on 8/11/2023Ownership: 1.726%Osaic Holdings Inc.Bought 10,000 shares on 8/10/2023Ownership: 1.835%Bank of Montreal CanBought 74,627 shares on 8/2/2023Ownership: 0.308%View All Institutional Transactions THTX Stock - Frequently Asked Questions Should I buy or sell Theratechnologies stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" THTX shares. View THTX analyst ratings or view top-rated stocks. What is Theratechnologies' stock price forecast for 2023? 3 equities research analysts have issued 12-month price objectives for Theratechnologies' shares. Their THTX share price forecasts range from $36.00 to $36.00. On average, they anticipate the company's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 1,543.8% from the stock's current price. View analysts price targets for THTX or view top-rated stocks among Wall Street analysts. How have THTX shares performed in 2023? Theratechnologies' stock was trading at $3.5312 on January 1st, 2023. Since then, THTX stock has decreased by 38.0% and is now trading at $2.19. View the best growth stocks for 2023 here. Are investors shorting Theratechnologies? Theratechnologies saw a increase in short interest in August. As of August 31st, there was short interest totaling 83,500 shares, an increase of 126.9% from the August 15th total of 36,800 shares. Based on an average daily trading volume, of 204,300 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.4% of the company's shares are sold short. View Theratechnologies' Short Interest. When is Theratechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 26th 2023. View our THTX earnings forecast. How were Theratechnologies' earnings last quarter? Theratechnologies Inc. (NASDAQ:THTX) announced its quarterly earnings data on Wednesday, July, 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.16. The firm earned $17.55 million during the quarter. When did Theratechnologies' stock split? Shares of Theratechnologies reverse split on the morning of Monday, July 31st 2023. The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What guidance has Theratechnologies issued on next quarter's earnings? Theratechnologies issued an update on its FY 2023 earnings guidance on Thursday, July, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $82.00 million-$87.00 million, compared to the consensus revenue estimate of $91.66 million. What other stocks do shareholders of Theratechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Trevena (TRVN), Citius Pharmaceuticals (CTXR), Great Panther Mining (GPL), TherapeuticsMD (TXMD), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), ChromaDex (CDXC), Caladrius Biosciences (CLBS) and Chimerix (CMRX). What is Theratechnologies' stock symbol? Theratechnologies trades on the NASDAQ under the ticker symbol "THTX." Who are Theratechnologies' major shareholders? Theratechnologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include National Bank of Canada FI (0.56%), Osaic Holdings Inc. (1.84%), Osaic Holdings Inc. (1.84%), Cibc World Market Inc. (1.73%), Bank of Montreal Can (0.31%) and Two Sigma Securities LLC (0.22%). How do I buy shares of Theratechnologies? Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Theratechnologies' stock price today? One share of THTX stock can currently be purchased for approximately $2.19. How much money does Theratechnologies make? Theratechnologies (NASDAQ:THTX) has a market capitalization of $53.00 million and generates $80.06 million in revenue each year. The company earns $-47,240,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. How many employees does Theratechnologies have? The company employs 144 workers across the globe. Does Theratechnologies have any subsidiaries? The following companies are subsidiares of Theratechnologies: Katana, Pharma-G Inc., Theratechnologies Europe Inc., Theratechnologies Europe Limited, Theratechnologies Intercontinental Inc., and Theratechnologies U.S. Inc.Read More How can I contact Theratechnologies? Theratechnologies' mailing address is 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8. The official website for the company is www.theratech.com. The company can be reached via phone at (514) 336-7800, via email at communications@theratech.com, or via fax at 514-331-9691. This page (NASDAQ:THTX) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.